Claims:

Claim 1. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in ~~a method of~~ treating or preventing an age-related disease/condition selected from: age-related inflammation, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

Claim 2. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related disease/condition selected from: age-related inflammation, frailty, age-related increase in fat mass, sarcopenia, age-related hyperlipidaemia, age-related hypertriglyceridemia, age-related hypercholesterolemia, age-related liver steatosis, age-related non-alcoholic fatty liver disease (NAFLD), age-related non-alcoholic fatty liver (NAFL), age-related non-alcoholic steatohepatitis (NASH), age-related cardiovascular disease, age-related hypertension, age-related renal disease and age-related skin disease.

Claim 3. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in ~~a method of~~ treating or preventing frailty.

Claim 4. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing frailty.

Claim 5. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in ~~a method of~~ treating or preventing an age-related change in body composition.

Claim 6. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of treating or preventing an age-related change in body composition.

Claim 7. An agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling for use in ~~a method of~~ increasing the healthspan of a subject.

Claim 8. Use of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling in the manufacture of a medicament for use in a method of increasing the healthspan of a subject.

Claim 9. The agent for use according to any one of claims 1, 3, 5 or 7, or the use according to any one of claims claim 2, 4, 6 or 8, wherein the agent is selected from the group consisting of: an antibody or an

antigen-binding fragment thereof, a polypeptide, a peptide, a nucleic acid, an oligonucleotide, an aptamer or a small molecule.

Claim 10. The agent for use or the use according to any one of claims 1 to 9, wherein the agent is an agent capable of preventing or reducing the binding of interleukin 11 (IL-11) to a receptor for interleukin 11 (IL-11R).

Claim 11. The agent for use or the use according to any one of claims 1 to 10, wherein the agent is capable of binding to interleukin 11 (IL-11) or a receptor for interleukin 11 (IL-11R).

Claim 12. The agent for use or the use according to any one of claims 1 to 11, wherein the agent is an antibody or an antigen-binding fragment thereof.

Claim 13. The agent for use or the use according to any one of claims 1 to 12, wherein the agent is an anti-IL-11 antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof.

Claim 14. The agent for use or the use according to any one of claims 1 to 12, wherein the agent is an anti-IL-11Rα antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof.

Claim 15. The agent for use or the use according to any one of claims 1 to 11, wherein the agent is a decoy receptor for IL-11.

Claim 16. The agent for use or the use according to any one of claims 1 to 11, wherein the agent is a competitive inhibitor of IL-11.

Claim 17. The agent for use or the use according to any one of claims 1 to 9, wherein the agent is capable of preventing or reducing the expression of interleukin 11 (IL-11) or a receptor for interleukin 11 (IL-11R).

Claim 18. The agent for use or the use according to claim 17, wherein the agent is an antisense oligonucleotide capable of preventing or reducing the expression of IL-11.

Claim 19. The agent for use or the use according to claim 17, wherein the agent is an antisense oligonucleotide capable of preventing or reducing the expression of IL-11Rα.

Claim 20. The agent for use or the use according to any one of claims 1 to 19, wherein the method comprises administering the agent to a subject in which expression of interleukin 11 (IL-11) or a receptor for IL-11 (IL-11R) is upregulated.